Baxter (NYSE:BAX) is the front-runner in the chase for has emerged as the frontrunner to buy India’s Gland Pharma for as much as $1.2 billion, according to the Economic Times.
Hyderabad-based Gland, which is partially owned by private equity giant KKR, is a contract manufacturer of injectables. KKR bought a 40% stake for $191 million in November 2013; founders led by Ravi Penmetsa own the majority stake.
Hyderabad-based Gland, which is partially owned by private equity giant KKR, is a contract manufacturer of injectables. KKR bought a 40% stake for $191 million in November 2013; founders led by Ravi Penmetsa own the majority stake.
